Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 30,2020 No.4Detail

Research progress of estrogen receptor on prostate cancer

Published on Aug. 21, 2020Total Views: 16708 timesTotal Downloads: 3165 timesDownloadMobile

Author: Gang-Lin SU 1, 2 Kun HU 2, 3 Jun-Wen XIAO 3 Yu-Chen LIU 3*

Affiliation: 1. Department of Clinical Medicine, Shantou University Medical College, Shantou 515041, Guangdong Province, China 2. Urology Department, Shenzhen Second People′s Hospital, Clinical Medicine College of Anhui Medical University, Shenzhen 518000, Guangdong Province, China 3. State and Local Government Joint Engineering Laboratory of Synthetic Biology Medicine and Clinical Application of Key Technologies, Shenzhen Second Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518036, Guangdong Province, China

Keywords: Prostate cancer Estrogen receptor Oncogene

DOI: 10.12173/j.issn.1004-5511.2020.04.12

Reference: Su GN, Hu K, Xiao JW, Sun H, Liu YC. Research progress of estrogen receptor on prostate cancer[J]. Yixue Xinzhi Zazhi, 2020, 30(4): 320-327.DOI:10.12173/j.issn.1004-5511.2020.04.12.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Prostate cancer is the most common malignant tumor and the second most common cause of cancer death in men. Estrogen receptors (ERs) are member of steroid hormone receptor superfamily. The role of estrogen in prostate is mainly mediated by estrogen receptor 1 (ERα) and estrogen receptor 2 (ERβ). More and more evidences suggest that estrogen receptors play an important role in the occurrence, development and prognosis of prostate cancer, and the progression of castrated resistant prostate cancer (CRPC). This article will introduce the structure and function of estrogen receptors, summarize relevant research progress in prostate cancer, analyze potential molecular mechanism and clinical application of ERs in the development of prostate cancer, and provide a new view for the treatment of prostate cancer.

Full-text
Please download the PDF version to read the full text: download
References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.

2. Sun L, Zhou H, Liu H, et al. GAS2-Calpain2 axis contributes to the growth of leukemic cells[J]. Acta Biochim Biophys Sin (Shanghai), 2015, 47(10): 795-804. DOI: 10.1093/abbs/gmv080.

3. Chen W, Zheng R, Zeng H, et al. The updated incidences and mortalities of major cancers in China, 2011[J]. Chin J Cancer, 2015, 34(11): 502-507. DOI: 10.1186/s40880-015-0042-6.

4. Suzuki K, Inaba S, Takeuchi H, et al. Endocrine environment of benign prostatic hyper-plas-ia--relationships of sex steroid hormone levels with age and the size of the prostate[J]. Nihon Hinyokika Gakkai Zasshi, 1992, 83(5): 664-671. DOI: 10.5980/jpnjurol1989.83.664.

5. Gupta L, Thakur H, Sobti RC, et al. Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population[J]. Mol Cell Biochem, 2010, 335(1-2): 255-261. DOI: 10.1007/s11010-009-0275-2.

6. Ricke WA, Mcpherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ es-trogen production and estrogen receptor alpha signaling[J]. FASEB J, 2008, 22(5): 1512-1520. DOI: 10.1096/fj.07-9526com.

7. Risbridger GP, Ellem SJ, Mcpherson SJ. Estrogen action on the prostate gland: a critical mix of en-docrine and paracrine signaling[J]. J Mol Endocrinol, 2007, 39(3): 183-188. DOI: 10.1677/JME-07-0053.

8. Lau KM, To KF. Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer[J]. Int J Mol Sci, 2016, 17(9): 1434. DOI: 10.3390/ijms17091434.

9. Spencer-Segal JL, Tsuda MC, Mattei L, et al. Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation[J]. Neuroscience, 2012, 202: 131-146. DOI: 10.1016/j.neuroscience.2011.11.035.

10.  Lindberg MK, Weihua Z, Andersson N, et al. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice[J]. J Endocrinol, 2002, 174(2): 167-178. DOI: 10.1677/joe.0.1740167.

11.  Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proc Natl Acad Sci U S A, 1996, 93(12): 5925-2930. DOI: 10.1073/pnas.93.12.5925.

12.  Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of dis-ease[J]. Cancer Lett, 2010, 288(2): 133-148. DOI: 10.1016/j.canlet.2009.06.017.

13.  He S, Nelson ER. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator[J]. Maturitas, 2017, 104: 29-35. DOI: 10.1016/j.maturitas.2017.07.014.

14.  Zhao C, Gao H, Liu Y, et al. Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1[J]. Cancer Res, 2010, 70(12): 5174-5183. DOI: 10.1158/0008-5472.CAN-09-4407.

15.  Tao X, Xu L, Yin L, et al. Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-beta[J]. Cell Death Dis, 2017, 8(8): e2989. DOI: 10.1038/cddis.2017.391.

16.  Yang GS, Wang Y, Wang P, et al. Expression of oestrogen receptor-alpha and oestrogen recep-tor-beta in prostate cancer[J]. Chin Med J (Engl), 2007, 120(18): 1611-1615.

17.  Megas G, Chrisofos M, Anastasiou I, et al. Estrogen receptor (alpha and beta) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population[J]. Asian J Androl, 2015, 17(1): 98-105. DOI: 10.4103/1008-682X.136445.

18.  Asgari M, Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma[J]. Diagn Pathol, 2011, 6: 61. DOI: 10.1186/1746-1596-6-61.

19.  Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer[J]. Cancer Res, 2001, 61(14): 5331-5335.

20.  Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adeno-carcinoma[J]. Prostate, 2003, 54(2): 79-87. DOI: 10.1002/pros.10171.

21.  Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis[J]. Am J Pathol, 2004, 164(6): 2003-2012. DOI: 10.1016/s0002-9440(10)63760-1.

22.  Pandini G, Genua M, Frasca F, et al. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells[J]. Cancer Res, 2007, 67(18): 8932-8941. DOI: 10.1158/0008-5472.CAN-06-4814.

23.  Takizawa I, Lawrence M G, Balanathan P, et al. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity[J]. Oncotarget, 2015, 6(2): 604-616. DOI: 10.18632/oncotarget.2820.

24.  Royuela M, De Miguel MP, Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate[J]. J Endocrinol, 2001, 168(3): 447-454. DOI: 10.1677/joe.0.1680447.

25.  Attia DM, Ederveen AG. Opposing roles of ERα and ERβ in the genesis and progression of ad-enocarcinoma in the rat ventral prostate[J]. Prostate, 2012, 72(9): 1013-1022. DOI: 10.1002/pros.21507.

26.  Parray A, Siddique H R, Nanda S, et al. Castration-resistant prostate cancer: potential targets and therapies[J]. Biologics, 2012, 6: 267-276. DOI: 10.2147/BTT.S23954.

27.  Lehmusvaara S, Erkkila T, Urbanucci A, et al. Chemical castration and anti-androgens induce dif-ferential gene expression in prostate cancer[J]. J Pathol, 2012, 227(3): 336-345. DOI: 10.1002/path.4027.

28.  Rajan P, Sudbery IM, Villasevil ME, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy[J]. Eur Urol, 2014, 66(1): 32-39. DOI: 10.1016/j.eururo.2013.08.011.

29.  Mishra S, Tai Q, Gu X, et al. Estrogen and estrogen receptor alpha promotes malignancy and os-teoblastic tumorigenesis in prostate cancer[J]. Oncotarget, 2015, 6(42): 44388-44402. DOI: 10.18632/oncotarget.6317.

30.  Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer[J]. Oncotarget, 2014, 5(17): 7217-7259. DOI: 10.18632/oncotarget.2406.

31.  Kim J, Roh M, Doubinskaia I, et al. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53[J]. Oncogene, 2012, 31(3): 322-332. DOI: 10.1038/onc.2011.236.

32.  Wang J, Kobayashi T, Floc'h N, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc ex-pression in advanced prostate cancer[J]. Cancer Res, 2012, 72(18): 4765-4776. DOI: 10.1158/0008-5472.CAN-12-0820.

33.  Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer[J]. J Natl Cancer Inst, 2008, 100(11): 815-825. DOI: 10.1093/jnci/djn150.

34.  Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer[J]. Nat Commun, 2014, 5: 5383. DOI: 10.1038/ncomms6383.

35.  Celhay O, Yacoub M, Irani J, et al. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression[J]. J Urol, 2010, 184(5): 2172-2178. DOI: 10.1016/j.juro.2010.06.089.

36.  Fromont G, Yacoub M, Valeri A, et al. Differential expression of genes related to androgen and es-trogen metabolism in hereditary versus sporadic prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(6): 1505-1509. DOI: 10.1158/1055-9965.EPI-07-2778.

37.  Daniels G, Gellert L L, Melamed J, et al. Decreased expression of stromal estrogen receptor alpha and beta in prostate cancer[J]. Am J Transl Res, 2014, 6(2): 140-146.

38.  Linja MJ, Savinainen KJ, Tammela TL, et al. Expression of ERalpha and ERbeta in prostate cancer[J]. Prostate, 2003, 55(3): 180-186. DOI: 10.1002/pros.10242.

39.  Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer[J]. J Natl Cancer Inst, 2002, 94(5): 384-390. DOI: 10.1093/jnci/94.5.384.

40.  BONKHOFF H, FIXEMER T, HUNSICKER I, et al. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions [J]. Am J Pathol, 1999, 155(2): 641-7. DOI: 10.1016/S0002-9440(10)65160-7.

41.  HETZL A C, MONTICO F, LORENCINI R M, et al. Fibroblast growth factor, estrogen, and prolactin re-ceptor features in different grades of prostatic adenocarcinoma in elderly men [J]. Microsc Res Tech, 2013, 76(3): 321-30. DOI: 10.1002/jemt.22170.

42.  Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking es-trogen receptor beta[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15677-15682. DOI: 10.1073/pnas.95.26.15677.

43.  Lau KM, Laspina M, Long J, et al. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation[J]. Cancer Res, 2000, 60(12): 3175-3182.

44.  Silva RS, Lombardi APG, De Souza DS, et al. Activation of estrogen receptor beta (ERbeta) regulates the expression of N-cadherin, E-cadherin and beta-catenin in androgen-independent prostate cancer cells[J]. Int J Biochem Cell Biol, 2018, 96: 40-50. DOI: 10.1016/j.biocel.2018.01.008.

45.  Mak P, Leav I, Pursell B, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading[J]. Cancer Cell, 2010, 17(4): 319-332. DOI: 10.1016/j.ccr.2010.02.030.

46.  Goel HL, Mercurio AM. VEGF targets the tumour cell[J]. Nat Rev Cancer, 2013, 13(12): 871-882. DOI: 10.1038/nrc3627.

47.  Mak P, Chang C, Pursell B, et al. Estrogen receptor beta sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription[J]. Proc Natl Acad Sci USA, 2013, 110(12): 4708-4713. DOI: 10.1073/pnas.1221654110.

48.  Leav I, Lau KM, Adams JY, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carci-noma[J]. Am J Pathol, 2001, 159(1): 79-92. DOI: 10.1016/s0002-9440(10)61676-8.

49.  Zellweger T, Sturm S, Rey S, et al. Estrogen receptor beta expression and androgen receptor phos-phorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castra-tion-resistant disease [J]. Endocr Relat Cancer, 2013, 20(3): 403-413. DOI: 10.1530/ERC-12-0402.

50.  Oh WK. The evolving role of estrogen therapy in prostate cancer[J]. Clin Prostate Cancer, 2002, 1(2): 81-89. DOI: 10.3816/cgc.2002.n.009.

51.  Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice[J]. New Engl J Med, 2003, 348(7): 618-629. DOI: 10.1056/NEJMra022219.

52.  Raghow S, Hooshdaran MZ, Katiyar S, et al. Toremifene prevents prostate cancer in the transgenic adeno-carcinoma of mouse prostate model[J]. Cancer Res, 2002, 62(5): 1370-1376.

53.  Shazer RL, Jain A, Galkin AV, et al. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits an-drogen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial[J]. BJU Int, 2006, 97(4): 691-697. DOI: 10.1111/j.1464-410X.2006.05974.x.

54.  Fujimura T, Takahashi S, Kume H, et al. Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial[J]. BMC Cancer, 2015, 15: 836. DOI: 10.1186/s12885-015-1871-z.

55.  Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer[J]. J Urol, 2013, 189(1 Suppl): S45-50. DOI: 10.1016/j.juro.2012.11.016.  

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us